Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS mutation in pancreatic cancer
Ji Luo
Seminars in Oncology (2021) Vol. 48, Iss. 1, pp. 10-18
Open Access | Times Cited: 221

Showing 1-25 of 221 citing articles:

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
John H. Strickler, Hironaga Satake, Thomas J. George, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 33-43
Open Access | Times Cited: 267
Molecular Characterization ofKRASWild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip, Ibrahim Azar, Joanne Xiu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 12, pp. 2704-2714
Open Access | Times Cited: 121
Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
Silvius Stanciu, Florentina Ioniţă‐Radu, Constantin Ștefani, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10132-10132
Open Access | Times Cited: 76
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 71
Role of long non-coding RNAs in pancreatic cancer pathogenesis and treatment resistance- A review
Tohada M. AL‐Noshokaty, Abdallah Mansour, Rehab Abdelhamid, et al.
Pathology - Research and Practice (2023) Vol. 245, pp. 154438-154438
Closed Access | Times Cited: 51
Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary
Intae Moon, Jaclyn LoPiccolo, Sylvan C. Baca, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2057-2067
Open Access | Times Cited: 50
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 33
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Flávia Pereira, A I Ferreira, Celso A. Reis, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 398-398
Open Access | Times Cited: 42
Annual review of KRAS inhibitors in 2022
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115124-115124
Closed Access | Times Cited: 32
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study
Mark Ayoub, Carol Faris, Tajana Juranovic, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1625-1625
Open Access | Times Cited: 12
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 12
ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation
Furong Ma, Yulong Li, Mao-Hua Cai, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116387-116387
Closed Access | Times Cited: 10
Signaling pathways in liver cancer: pathogenesis and targeted therapy
Yangtao Xue, Yeling Ruan, Yali Wang, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 10
Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
Carina Peres, Ana I. Matos, Bárbara Carreira, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 33
Open Access | Times Cited: 9
The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
Faria Nusrat, Akshay Khanna, Aditi Jain, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2103-2103
Open Access | Times Cited: 9
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Tonia Kirschner, Matthias Müller, Daniel Rauh
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6044-6051
Closed Access | Times Cited: 9
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
Ou Li, Li Li, Yunru Sheng, et al.
Cancer Letters (2023) Vol. 574, pp. 216391-216391
Open Access | Times Cited: 18
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Zhiqing Lin, Keke Huang, Hui Guo, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114567-114567
Open Access | Times Cited: 16
Metastatic Pancreatic Cancer: Where Are We?
Abraham Hernández-Blanquisett, Valeria Quintero-Carreño, María Cristina Martínez‐Ávila, et al.
Oncology Reviews (2024) Vol. 17
Open Access | Times Cited: 7
Ultraspecific One-Pot CRISPR-Based “Green-Yellow-Red” Multiplex Detection Strategy Integrated with Portable Cartridge for Point-of-Care Diagnosis
Shuaiwei Chen, Cui Wu, Chunyan Qian, et al.
Analytical Chemistry (2024)
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top